A study done on Toxoplasma gondii, a parasite commonly hosted in cats known for the potential complications it cause for human pregnancies, suppressed the immune system and is found to have some positive effects on Alzheimer's disease mouse models .This parasite promotes a significant decrease in the amount of b-amyloid plaque deposition, a hallmark of Alzheimer's disease, and not to forget the better performance in behavior tests like a water maze.
Neurodegenerative process is thought to involve the accumulation of abnormal toxic proteins and the spread of these toxic proteins between neurons, which may be contagious through their synaptic connections.Two distinct patterns in of brain damage predicted by studies one studying how brain circuits wire up structurally in their natural manner and the other their functional connections, converged on a remarkably similar model which predicted the sites of degeneration in each forms of dementia .These studies have been proved significant since the models to predict and study the human neural degeneration has remained elusive.
The early ideas dealt with the antioxidant’s and CSF biomarkers have been proved wrong. Recent studies reveal that there is no association between an antioxidant combination of vitamin E, vitamin C and α-lipoic acid (E/C/ALA) and the changes Alzheimer’s related biomarkers in the cerebrospinal fluid. Oxidative impairment is linked to aging and is common in individuals with Alzheimer's disease but the risk can be reduced by diet rich in antioxidants.
or other forms of dementia , compared to those of normal weight and also promotes cardiovascular diseases . A simple study says that people with higher BMIs and larger waist size scored the worst in the cognitive tests. But there do was some exceptions where there happen to be no associations between the cognitive abilities and obesity.Studies reveals that the People over the aged from 60 to 70 years with high levels of visceral fat have a greater risk of brain decline there by resulting in Alzheimer’s
by propagating in all directions. Studies concluded that a nerve region's connectedness to a disease hot spot trumps overall connectedness, spatial proximity and loss of growth-factor support in predicting its vulnerability to the spread of Alzheimer’s.Studies on Brain imaging suggest that Alzheimer’s and other forms of most prevalent dementia’s may spread within nerve networks in the brain by moving directly between connected neurons, in a way
A new technology, recently approved by the FDA, allows researchers to detect amyloid plaques that often suggest Alzheimer's disease. Created by Eli Lilly, Amyvid is a drug that, when used before a PET scan, will highlight amyloid plaque in the brain. This method is much more preferable for diagnosis than the current method of performing an autopsy.
A new study shows that reducing the iron levels in blood plasma may help protect the brain from changes. There is previous evidence that there are changes in the way the human body handles iron and other metals (zinc, cooper) before it shows Alzheimer's symptoms. In the study, rats are fed a high cholesterol diet which causes them to build up plaques of a protein called beta-amyloid and develop changes in the tau proteins. The study deals with a new drug called deferiprone which lowered the iron concentration in the blood plasma of the rabbit and the level of beta-amyloid and the tau proteins in the brain.
At the University of South Florida (USF) researchers have discovered that the amyloid precursor protein (APP) which is associated with Alzheimer's Disease regulates its own growth. This discovery has the potential to allow scientists to treat and possible prevent the disease by controlling the regulation of the protein. Through their research at USF, it has been determined that the growth of APP is dependent on an enzyme (BACE1) excreted by the amyloid leading to the theory that, if the reaction between the BACE1 and APP was blocked, Alzheimer's disease may see its end.
Researchers have shown that elevated pulse pressures in older humans with Alzheimer's disease are at a higher risk to get Cerebrovascular disease. Recent studies have shown that patients with Alzheimer's disease that have a high pulse pressure may impair the clearance of beta-amyloid from the brain. Other studies show that high pulse pressures increases the chance of Cerebrovascular disease which contributes to the cause of Alzheimer's disease.
A groundbreaking new test for the early detection of Alzheimer's disease is being developed at a research facility just north of Sydney, Australia. Currently, the only prevalent tests of such nature are invasive and expensive. However, the test being developed in Syndey is a cheap blood test that checks for a change in levels of a specific protein marker over a year in order to determine if a patient is in deed affected by the lethal disease. The earlier Alzheimer's is detected, the more likely it can be slowed and even stopped.
For more exciting research progress, please visit:
Roskamp Research Scientists Dr. Paris, Dr. Michael Mullan and others have discovered novel anticancer activity for a shortThe inhibition of angiogenesis is regarded as a promising avenue for cancer treatment. Although some antiangiogenic compounds are in the process of development and testing, these often prove ineffective in vivo, therefore the search for new inhibitors is critical. We have recently identified a ten amino acid fragment of the Alzheimer Abeta peptide that is anti-angiogenic both in vitro and in vivo. In the present study, we investigated the antitumoral potential of this decapeptide using human MCF-7 breast carcinoma xenografts nude mice. We observed that this decapeptide was able to suppress MCF-7 tumor growth more potently than the antiestrogen tamoxifen. Inhibition of tumor vascularization as determined by PECAM-1 immunostaining and decreased tumor cell proliferation as determined by Ki67 immunostaining were observed following treatment with the Abeta fragment. In vitro, this peptide had no direct impact on MCF-7 tumor cell proliferation and survival suggesting that the inhibition of tumor growth and tumor cell proliferation observed in vivo is related to the antiangiogenic activity of the peptide. Taken together these data suggest that this short Abeta derivative peptide may constitute a new antitumoral agent.
For more information on the Roskamp Institute and Alzheimer’s please visit: